Clinical effect of obesity on N‐terminal pro‐B‐type natriuretic peptide cut‐off concentrations for the diagnosis of acute heart failure
Authors:
Open Access
- 8 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (9) , 1545-1554
Abstract
Aims: Obese patients have lower natriuretic peptide concentrations. We hypothesized that adjusting the concentration of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) for obesity could further increase its clinical utility in the early diagnosis of acute heart failure (AHF). Methods and results: This hypothesis was tested in a prospective diagnostic study enrolling unselected patients presenting to the emergency department with acute dyspnoea. Two independent cardiologists/internists centrally adjudicated the final diagnosis using all individual patient information including cardiac imaging. NT‐proBNP plasma concentrations were applied: first, using currently recommended cut‐offs; second, using cut‐offs lowered by 33% with body mass index (BMI) of 30–34.9 kg/m 2 and by 50% with BMI ≥ 35 kg/m 2 . Among 2038 patients, 509 (25%) were obese, of which 271 (53%) had AHF. The diagnostic accuracy of NT‐proBNP as quantified by the area under the receiver‐operating characteristic curve was lower in obese versus non‐obese patients (0.890 vs. 0.938). For rapid AHF rule‐out in obese patients, the currently recommended cut‐off of 300 pg/ml achieved a sensitivity of 96.7% (95% confidence interval [CI] 93.8–98.2%), ruling out 29% of patients and missing 9 AHF patients. For rapid AHF rule‐in, the age‐dependent cut‐off concentrations (age 75 years: 1800 pg/ml) achieved a specificity of 84.9% (95% CI 79.8–88.9%). Proportionally lowering the currently recommended cut‐offs by BMI increased sensitivity to 98.2% (95% CI 95.8–99.2%), missing 5 AHF patients; reduced the proportion of AHF patients remaining in the ‘gray zone’ (48% vs. 26%; p = 0.002), achieving a specificity of 76.5% (95% CI 70.7–81.4%). Conclusions: Adjusting NT‐proBNP concentrations for obesity seems to further increase its clinical utility in the early diagnosis of AHF.Keywords
Funding Information
- Abbott Laboratories
- Alere
- Roche
- Schweizerische Herzstiftung
- Singulex
- Universitätsspital Basel
- Universität Basel
This publication has 31 references indexed in Scilit:
- Effect of Weight Loss After Weight Loss Surgery on Plasma N-Terminal Pro-B-Type Natriuretic Peptide LevelsThe American Journal of Cardiology, 2010
- Understanding Amino-Terminal Pro–B-Type Natriuretic Peptide in ObesityThe American Journal of Cardiology, 2008
- How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failureAmerican Heart Journal, 2006
- NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patientsEuropean Heart Journal, 2005
- The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) studyThe American Journal of Cardiology, 2005
- Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudyAmerican Heart Journal, 2005
- Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute DyspneaNew England Journal of Medicine, 2004
- B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart FailureCirculation, 2002
- Interval Estimation for a Binomial ProportionStatistical Science, 2001
- Comparative analysis of two ratesStatistics in Medicine, 1985